Endocrine Abstracts

Current therapies for acromegaly are unsatisfactory for some patients. High dose thiazoledinedines have been reported to shrink tumor size and reduce serum GH levels in animal models of acromegaly. To study the effects of increasing doses of rosiglitazone on serum GH and IGF1 concentrations in acromegalic patients, we designed a phase two clinical trial. We enrolled five consecutive patients with active acromegaly uncontrolled under conventional therapies. They received increa...

Context: Acromegalic patients have a high-risk cardiovascular profile. However, the determinants of cardiovascular risk factors and major cardiovascular events (MACE), which may develop after diagnosis of acromegaly, are not fully understood.Objectives: To identify the predictors for systemic comorbidities and MACE, after diagnosis of disease. The role of therapy for acromegaly on the occurrence of such complications was also evaluated.<p class="abst...